Galanthamine	galanthamine	O	O
hydrobromide	hydrobromide	O	O
,	,	O	O
a	a	O	O
longer	longer	O	O
acting	acting	O	O
anticholinesterase	anticholinesterase	O	O
drug	drug	O	O
,	,	O	O
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
the	the	O	O
central	central	O	O
effects	effects	O	O
of	of	O	O
scopolamine	scopolamine	S_chemical	O
(Hyoscine).Galanthamine	(hyoscine).galanthamine	O	O
hydrobromide	hydrobromide	O	O
,	,	O	O
an	an	O	O
anticholinesterase	anticholinesterase	O	O
drug	drug	O	O
capable	capable	O	O
of	of	O	O
penetrating	penetrating	O	O
the	the	O	O
blood-brain	blood-brain	O	O
barrier	barrier	O	O
,	,	O	O
was	was	O	O
used	used	O	O
in	in	O	O
a	a	O	O
patient	patient	O	O
demonstrating	demonstrating	O	O
central	central	O	O
effects	effects	O	O
of	of	O	O
scopolamine	scopolamine	S_chemical	O
(	(	O	O
hyoscine	hyoscine	O	O
)	)	O	O
overdosage	overdosage	O	O
.	.	O	O

It	it	O	O
is	is	O	O
longer	longer	O	O
acting	acting	O	O
than	than	O	O
physostigmine	physostigmine	O	O
and	and	O	O
is	is	O	O
used	used	O	O
in	in	O	O
anaesthesia	anaesthesia	O	O
to	to	O	O
reverse	reverse	O	O
the	the	O	O
non-depolarizing	non-depolarizing	O	O
neuromuscular	neuromuscular	O	O
block	block	O	O
.	.	O	O

However	however	O	O
,	,	O	O
studies	studies	O	O
into	into	O	O
the	the	O	O
dose	dose	O	O
necessary	necessary	O	O
to	to	O	O
combating	combating	O	O
scopolamine	scopolamine	S_chemical	O
intoxication	intoxication	O	O
are	are	O	O
indicated	indicated	O	O
.	.	O	O

